Results 11 to 20 of about 2,105 (152)

Anti‐Melanoma Differentiation‐Associated Gene 5 Antibody‐Positive Interstitial Lung Disease, Induced by Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma [PDF]

IJU Case Reports
Introduction Anti‐melanoma differentiation‐associated gene 5 antibody‐positive interstitial lung disease is a rare but fatal adverse event following immune checkpoint inhibitor treatment for cancers.
Akira Saito, Hiroki Ishihara, Hanae Kondo, Toshio Takagi, Yasunobu Hashimoto   +4 more
doaj   +3 more sources

A Case of Upper Tract Urothelial Carcinoma With Neuroendocrine Differentiation Successfully Treated With Enfortumab Vedotin and Pembrolizumab [PDF]

IJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction Upper tract urothelial carcinoma with neuroendocrine differentiation (UC‐NE) is extremely rare and generally associated with aggressive behavior and poor prognosis. Optimal treatment strategies remain unclear, particularly regarding the role of nectin‐4–targeted therapy. Case Presentation A 61‐year‐old man was diagnosed with UC‐NE
Kosei Taniguchi, Mamoru Hashimoto, Takahito Nakayama, Saizo Fujimoto, Shingo Toyoda, Takashi Kikuchi, Marco Antonio De Velasco, Osamu Maenishi, Takafumi Minami, Kazutoshi Fujita   +9 more
wiley   +2 more sources

Case report series: Pembrolizumab and enfortumab vedotin in plasmacytoid urothelial carcinoma [PDF]

Frontiers in Oncology
Plasmacytoid urothelial carcinoma (PUC) is a rare and aggressive histologic subtype of urothelial carcinoma with no well-established treatment. Recently, the combination of pembrolizumab and enfortumab vedotin has become the standard of care for locally ...
Susanna G. Bowen, Derek B. Allison, Derek B. Allison, Derek B. Allison, Patrick J. Hensley, Patrick J. Hensley, Patrick J. Hensley, Zin W. Myint, Zin W. Myint   +8 more
doaj   +2 more sources

Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis [PDF]

International Journal of Cancer, Volume 158, Issue 6, Page 1654-1665, 15 March 2026.
What's new? New antibody‐drug conjugates (ADCs) and immunotherapies have helped expand treatment options for urothelial carcinoma (UC). Clinical trials suggest that the ADC enfortumab vedotin (EV) and the immunotherapeutic agent pembrolizumab, when used in combination, are especially effective against UC.
Dora Niedersuess‐Beke, Karl Mayrhofer, Johanna Krauter, Johannes Franke, Dominic Vais, Maximillian Pallauf, David Kiesl, Ferdinand Luger, Jacob Pfuner, Angelika Terbuch, Thomas Bauernhofer, Jasmin Spielgelberg, Andreas Banner, Stefan Aufderklamm, Clemens Wiesinger, Susanne Schnabel, Simon Peter Gampenrieder, Josef Mühlmann, Sonia Vallet, Sabine Weibrecht, Franz Stoiber, Haleh Andalibi, Harun Fajkovic, Hossein Taghizadeh, Jan Miechowiecki, Roman Taedcke, Daniel Heintel, Shahrokh F. Shariat, Martin Pichler, Wolfgang Hilbe, Renate Pichler   +30 more
wiley   +2 more sources

Salvage Surgery for Primary Renal Pelvic Urothelial Carcinoma After Enfortumab Vedotin: A Case of Durable Remission With Nectin‐4 Loss [PDF]

IJU Case Reports
Introduction Enfortumab vedotin is a standard therapy for advanced urothelial carcinoma, but its efficacy may be limited by acquired resistance and spatial heterogeneity of Nectin‐4 expression.
Takahito Wakamiya, Yuya Iwahashi, Hiroki Kawabata, Satoshi Muraoka, Shimpei Yamashita, Fumiyoshi Kojima, Yasuo Kohjimoto   +6 more
doaj   +2 more sources

Double metastatic cancer with lung and urothelial carcinoma responding to enfortumab vedotin: a case report and review of the literature [PDF]

Journal of Medical Case Reports
Background For patients with metastatic lung adenocarcinoma, systemic therapy with platinum-based chemotherapy associated with immunotherapy is the standard of care. The treatment decision seems to be more difficult with a second cancer occurrence during
Magali Ravoire, Léa Vazquez
doaj   +2 more sources

Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma [PDF]

Scientific Reports
Enfortumab Vedotin Ineligible criTeriA (EVITA) were proposed for the selection of patients to receive enfortumab vedotin (EV) and pembrolizumab treatment. However, the usefulness of these criteria has not been fully verified.
Takafumi Fukushima, Kazuyuki Numakura, Masanao Shinohara, Yohei Kawashima, Yuya Sekine, Kanami Mori, Mizuki Kobayashi, Himawari Asanuma, Takaki Ichiyama, Hisashi Sakurai, Kai Ozaki, Naoki Fujita, Teppei Okamoto, Hayato Yamamoto, Takahiro Yoneyama, Satoshi Sato, Tomonori Habuchi, Chikara Ohyama, Shingo Hatakeyama   +18 more
doaj   +2 more sources

Early-onset fatal toxic epidermal necrolysis after first-cycle enfortumab vedotin in an elderly patient with metastatic urothelial carcinoma [PDF]

Urology Case Reports
An 86-year-old man with metastatic urothelial carcinoma developed fever, mucosal erosions, and rapidly progressive widespread erythema shortly after completing the first cycle of enfortumab vedotin (EV).
Fumihiro Ito, Koki Kobayashi, Yurika Sawasaki, Gaku Hayashi, Shunsuke Kamijo, Akitaka Shibata, Takashi Fujita   +6 more
doaj   +2 more sources

Enfortumab Vedotin in urothelial cancer

Therapeutic Advances in Urology, 2020
The treatment landscape for metastatic urothelial cancer (mUC) beyond first-line platinum-based chemotherapy has changed significantly over the last 5 years with the recent approvals of the immune checkpoint inhibitors (ICIs), fibroblast growth factor ...
Marie Alt, Carlos Stecca, Swanee Tobin, Di Maria Jiang, Srikala S. Sridhar   +4 more
doaj   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source